Financial Data and Key Metrics Changes - The company has seen significant growth in its integrated delivery network (IDN) sales, which were up 12 times from 2024 to 2023, indicating a strong market acceptance of its product [21] - The redesign of Medicare Part D is expected to provide a significant tailwind, with patients now having a $2,000 cap on out-of-pocket expenses, which is anticipated to drive higher fill rates and net sales [42][45] Business Line Data and Key Metrics Changes - The company’s product, Furosex, is designed to deliver 100% bioavailable furosemide, which is equivalent to the IV treatment in hospitals, allowing patients to manage their condition at home [6][14] - The approval for chronic kidney disease (CKD) indication is expected to expand the total addressable market (TAM), with approximately 700,000 patients having CKD without heart failure, and many patients suffering from both conditions [27][29] Market Data and Key Metrics Changes - The company is focusing on integrated delivery networks (IDNs) where physicians are financially aligned with hospitals, which enhances the value proposition of Furosex [19] - There is a noted difference in how various IDNs operate, with larger systems like Kaiser and the VA being more closed and structured, while smaller IDNs may require tailored protocols for best practices [25][26] Company Strategy and Development Direction - The company aims to capture the value proposition of its product by focusing on early intervention in heart failure patients to prevent hospitalizations [10][17] - The introduction of an auto-injector is expected to simplify the treatment process, reduce costs of goods sold (COGS) by 70%, and extend intellectual property protection until 2040 [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the impact of the Medicare redesign, which is expected to facilitate patient access to the drug and drive sales growth [39][46] - The expansion of the sales force is anticipated to take time to show results, but early indicators suggest positive trends in sales as more representatives engage with healthcare providers [54] Other Important Information - The company has developed internal protocols for IDNs to share best practices, which is crucial for smaller networks that may lack established guidelines [24][26] - The management highlighted the importance of addressing the needs of patients who are discharged from hospitals with residual congestion, as this presents an opportunity for Furosex to prevent readmissions [15][17] Q&A Session Summary Question: How does the company see the balance between preventing hospitalizations and reducing length of stay? - The company aims to intervene early when patients first show signs of worsening heart failure, thus preventing the need for hospitalization [10][11] Question: Are hospitals with higher readmission rates embracing Furosex? - There is a need for education among hospital staff, particularly among cardiologists who may not be fully aware of the benefits of Furosex [18] Question: How does the CKD indication expand opportunities? - The CKD indication opens up a new market segment, particularly for patients with cardiorenal disease, which is expected to drive growth [27][29] Question: What are the expected impacts of the Medicare Part D redesign? - The redesign is anticipated to lower out-of-pocket costs for patients, thereby increasing fill rates and driving sales growth [39][45] Question: How does the auto-injector fit into the company's strategy? - The auto-injector is expected to simplify the treatment process and significantly reduce costs, while also appealing to a broader patient base [49][51]

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25.93%. A quarter ago, it was expected that this company would post a loss of $0.40 per share when it actually produced a loss of $0.35, delivering a surprise of 12.50%.Over the last four quarters, the company has ...

scPharmaceuticals (SCPH) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 a reminder, today's conference call is being recorded. I would now like to turn the conference over to Wim Thorpe, Investor Relations, to cover forward looking statements. Wim, please go ahead. Speaker1 Thank you, operator. Before beginning this afternoon's earnings call, we would like to highlight the following forward looking statements. All statements on this conference call, other than historical facts, are forward looking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of incorporation or organization) 25 Mall Road, Suite 203 01803 Burlington, Massachusetts (Zip Code) (Address of principal executive office) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcas ...

Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14th, at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceutica ...

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs. Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today annou ...

scPharmaceuticals (SCPH) 2025 Conference May 07, 2025 09:30 AM ET Speaker0 Everybody, thank you for joining us at the Citizens Life Science Conference. I'm Jason Butler. I'm one of the biopharma analysts here at Citizens. Excited to kick off this conference this week. Specifically excited to be joined by our first company SC Pharmaceuticals. SC Pharma is a company focused on the cardio renal space, is launching a product called Furosex. Had an exciting announcement just a few weeks ago with a label expansio ...

BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: Wedne ...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and we ...